Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia.
Adult
Aged
Australia
Coronary Vessel Anomalies
/ diagnosis
DNA Mutational Analysis
Databases, Genetic
Europe
Female
Fibromuscular Dysplasia
/ diagnosis
Genetic Predisposition to Disease
HEK293 Cells
Humans
Loss of Function Mutation
Male
Middle Aged
Mutation, Missense
Phenotype
Predictive Value of Tests
Receptors, Epoprostenol
/ genetics
Risk Assessment
Risk Factors
United States
Vascular Diseases
/ congenital
Fibromuscular dysplasia
Prostacyclin signalling
Rare loss-of-function variants
Spontaneous coronary artery dissection
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
21 03 2021
21 03 2021
Historique:
received:
22
01
2020
revised:
14
05
2020
accepted:
07
06
2020
pubmed:
13
6
2020
medline:
5
1
2022
entrez:
13
6
2020
Statut:
ppublish
Résumé
Fibromuscular dysplasia (FMD) and spontaneous coronary artery dissection (SCAD) are related, non-atherosclerotic arterial diseases mainly affecting middle-aged women. Little is known about their physiopathological mechanisms. We aimed to identify rare genetic causes to elucidate molecular mechanisms implicated in FMD and SCAD. We analysed 29 exomes that included familial and sporadic FMD. We identified one rare loss-of-function variant (LoF) (frequencygnomAD = 0.000075) shared by two FMD sisters in the prostaglandin I2 receptor gene (PTGIR), a key player in vascular remodelling. Follow-up was conducted by targeted or Sanger sequencing (1071 FMD and 363 SCAD patients) or lookups in exome (264 FMD) or genome sequences (480 SCAD), all independent and unrelated. It revealed four additional LoF allele carriers, in addition to several rare missense variants, among FMD patients, and two LoF allele carriers among SCAD patients, including one carrying a rare splicing mutation (c.768 + 1C>G). We used burden test to test for enrichment in patients compared to gnomAD controls, which detected a putative enrichment in FMD (PTRAPD = 8 × 10-4), but not a significant enrichment (PTRAPD = 0.12) in SCAD. The biological effects of variants on human prostaclycin receptor (hIP) signalling and protein expression were characterized using transient overexpression in human cells. We confirmed the LoFs (Q163X and P17RfsX6) and one missense (L67P), identified in one FMD and one SCAD patient, to severely impair hIP function in vitro. Our study shows that rare genetic mutations in PTGIR are enriched among FMD patients and found in SCAD patients, suggesting a role for prostacyclin signalling in non-atherosclerotic stenosis and dissection.
Identifiants
pubmed: 32531060
pii: 5856738
doi: 10.1093/cvr/cvaa161
pmc: PMC7983006
doi:
Substances chimiques
PTGIR protein, human
0
Receptors, Epoprostenol
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1154-1165Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : British Heart Foundation
ID : PG/13/96/30608
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : P01 HL147823
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139672
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148167
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL076491
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007824
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128300
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL103866
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130423
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024989
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL135093
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
J Biol Chem. 2011 Mar 4;286(9):7060-9
pubmed: 21189259
Mayo Clin Proc. 1987 Oct;62(10):931-52
pubmed: 3309488
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Arch Surg. 1975 May;110(5):561-6
pubmed: 1131001
Vasc Med. 2019 Apr;24(2):164-189
pubmed: 30648921
J Am Coll Cardiol. 2019 Jan 8;73(1):58-66
pubmed: 30621952
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Med Hypotheses. 2014 Jul;83(1):21-4
pubmed: 24810675
Am J Hum Genet. 2018 Oct 4;103(4):522-534
pubmed: 30269813
J Hypertens. 2015 Sep;33(9):1802-10; discussion 1810
pubmed: 26147384
Int J Mol Sci. 2018 May 21;19(5):
pubmed: 29883369
Circ Res. 2008 Apr 25;102(8):986-93
pubmed: 18323528
Circ Genom Precis Med. 2019 Apr;12(4):e002437
pubmed: 30888838
BMC Bioinformatics. 2014 Jul 19;15:247
pubmed: 25038816
Circulation. 2018 May 8;137(19):e523-e557
pubmed: 29472380
J Hypertens. 2018 Jun;36(6):1318-1325
pubmed: 29528871
Pharmacol Rev. 2012 Jul;64(3):540-82
pubmed: 22679221
J Surg Res. 1978 Mar;24(3):167-77
pubmed: 633881
Circulation. 2012 Jun 26;125(25):3182-90
pubmed: 22615343
Nucleic Acids Res. 2016 Jul 8;44(W1):W117-21
pubmed: 27131783
Eur Heart J. 2018 Sep 21;39(36):3353-3368
pubmed: 29481627
Transl Res. 2012 Feb;159(2):64-79
pubmed: 22243791
PLoS Genet. 2016 Oct 28;12(10):e1006367
pubmed: 27792790
Cardiovasc Res. 2020 Jan 1;116(1):63-77
pubmed: 31424497
Br J Pharmacol. 2012 May;166(2):447-56
pubmed: 22233238
J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89
pubmed: 27050191